Swedish Orphan Biovitrum AB · OMXSTO:SOBI
Swedish Orphan Biovitrum AB — Investor Presentation (March 2011)
7 slides from Swedish Orphan Biovitrum AB's investor presentation, Mar 29, 2011
Slide 1: Announcement of rights issue
Announcement of rights issue 29 March, 2011
Slide 2: Integration completed
Integration completed • Successful merger of Biovitrum and Swedish Orphan – Complementary operations/good fit • Synergies of SEK 100 million achieved on an annualized basis – 55 overlapping positions eliminated – Support systems streamlined – Move into one common head office – Alignment of global di
Slide 3: Implementation of strategy
Implementation of strategy • Seven ongoing product launches • All phase III studies run according to plan • Five new business development deals; continued intensive BD-activities • Cost structure being addressed – downsizing of early research and CMC • Sobi’s organization strengthened – Resources fo
Slide 4: Announcement of cost reductions
Announcement of cost reductions • Cost reductions of approx. SEK 100 million on an annual basis – Generated gradually during 2011 with full effect as of 2012 • Implemented in all functions – Reduction of approx. 70 positions, mostly within preclinical development, CMC and Manufacturing and Quality C
Slide 5: Reasons for rights issue
Reasons for rights issue • Improves capacity to implement strategy and reach financial goals – Expansion of the product portfolio through additional in-licensing, distribution agreements and product acquisitions – Commercialization of new products – Continued geographical expansion through extension
Slide 6: Rights issue terms
Rights issue terms Offering type • Fully underwritten rights issue of common shares Size • Gross proceeds of SEK 600 million Envisaged timetable • Rights issue announced: 29 March • Q1 report: changed from 28 April to 20 April • Rights issue terms announced: 27 April • AGM decision on proposed trans
Slide 7: Rare disease strategy with strong platform for profitable growth
Rare disease strategy with strong platform for profitable growth • Attractive market – Well-defined market segment with attractive growth opportunities • Diversified portfolio – Diversified portfolio of orphan and niche specialist pharmaceuticals • Strong commercial presence – Strong European and em
Swedish Orphan Biovitrum — Investor Presentation (March 2011) on 6ix